SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In conclusion, our meta-analysis is the most comprehensive and updated assessment of placebo-controlled or head-to-head RCTs of adult individuals with NAFLD using various SGLT-2 inhibitors to specifically treat NAFLD.